Premature Menopause — MCQs
Which serum level is increased in premature ovarian failure?
A female patient presents with hirsutism, amenorrhea, and obesity. What is the most likely diagnosis?
A teenage girl presented with irregular cycles and increased facial hair. Her ovaries showed increased volume. Which of the following are used in the first line treatment? 1. Laparoscopic ovarian drilling 2. Anti-androgens 3. Lifestyle modifications 4. Combined oral contraceptive pills
All of the following are tests done for Turner mosaic screening except?
A 30-year-old housewife reports with 6 months amenorrhea. Her serum LH and FSH are high with low estradiol levels. What is the most likely cause of amenorrhea in this context?
All of the following are true about hot flushes EXCEPT:
A 46-year-old woman presents for her annual examination. Her main complaint is frequent sweating episodes with a sensation of intense heat starting at her upper chest and spreading up to her head. These have been intermittent for the past 6 to 9 months but are gradually worsening. She has three to four flushing/sweating episodes during the day and two to three at night. She occasionally feels her heart race for about a second, but when she checks her pulse it is normal. She reports feeling more tired and has difficulty with sleep due to sweating. She denies major life stressors. She also denies weight loss, weight gain, or change in bowel habit. Her last menstrual cycle was 3 months ago. Physical examination is normal. Which treatment is most appropriate in alleviating this woman's symptoms?
Which of the following is NOT effective in controlling the hot flushes of menopause in a woman?
For a menopausal patient having hot flashes, which of the following can be given as treatment?
In menopause, which of the following is seen:
Premature Menopause Indian Medical PG Practice Questions and MCQs
Question 1: Which serum level is increased in premature ovarian failure?
- A. Serum Inhibin
- B. Serum FSH (Correct Answer)
- C. Serum Estradiol
- D. Serum Progesterone
Explanation: ***Serum FSH*** - In **premature ovarian failure**, the ovaries fail to produce sufficient estrogen and inhibin, leading to a loss of negative feedback on the pituitary gland. - This lack of negative feedback results in continuously **elevated levels of FSH** as the pituitary tries to stimulate the non-responsive ovaries. *Serum Inhibin* - **Inhibin** is a hormone produced by ovarian granulosa cells, which normally inhibits FSH secretion. - In premature ovarian failure, due to ovarian dysfunction, **inhibin levels are typically decreased**, not increased. *Serum Estradiol* - **Estradiol** is the primary estrogen produced by the ovaries. - In premature ovarian failure, the ovaries are failing, resulting in **decreased production of estrogen/estradiol**. *Serum Progesterone* - **Progesterone** is primarily produced after ovulation by the corpus luteum. - In premature ovarian failure, ovulation is impaired or absent, leading to **low or undetectable progesterone levels**.
Question 2: A female patient presents with hirsutism, amenorrhea, and obesity. What is the most likely diagnosis?
- A. Androgen-secreting ovarian tumor
- B. Congenital adrenal hyperplasia
- C. Cushing's syndrome
- D. Polycystic Ovary Syndrome (PCOS) (Correct Answer)
Explanation: ***Polycystic Ovary Syndrome (PCOS)*** - **Hirsutism**, **amenorrhea** (or oligomenorrhea), and **obesity** are classic clinical features of PCOS, reflecting hyperandrogenism and insulin resistance [2]. - PCOS is a diagnosis of exclusion and involves chronic anovulation and polycystic ovaries on ultrasound [3], though these are not explicitly mentioned, the constellation of symptoms strongly points to it. *Androgen-secreting ovarian tumor* - While it can cause **hirsutism** and **amenorrhea**, the onset is typically **rapid** and severe, with very high androgen levels, and obesity is not a primary feature. - Ovarian tumors are generally less common than PCOS and may present with a palpable mass or specific imaging findings. *Congenital adrenal hyperplasia* - This genetic condition often presents in childhood or adolescence with varying degrees of **virilization** and menstrual irregularities due to enzyme deficiencies in cortisol synthesis [1]. - While it causes **hirsutism** and potentially **amenorrhea**, obesity is not a direct consequence, and the patient's age of presentation and specific symptom pattern are less typical for adult-onset CAH in this context. *Cushing's syndrome* - Characterized by **central obesity**, **moon facies**, **buffalo hump**, **striae**, and proximal muscle weakness due to chronic glucocorticoid excess. - Although it can cause **menstrual irregularities** and mild **hirsutism** [2], the overall clinical picture including the absence of other specific Cushingoid features makes it less likely than PCOS.
Question 3: A teenage girl presented with irregular cycles and increased facial hair. Her ovaries showed increased volume. Which of the following are used in the first line treatment? 1. Laparoscopic ovarian drilling 2. Anti-androgens 3. Lifestyle modifications 4. Combined oral contraceptive pills
- A. 2,3,4 (Correct Answer)
- B. 1,2,3
- C. 1,2,4
- D. 1,3,4
Explanation: ***2,3,4 (Correct Answer)*** - **Lifestyle modifications (3)** are the foundational first-line intervention for all PCOS patients, particularly those who are overweight or obese, as they improve insulin sensitivity, reduce androgen levels, and improve both metabolic and reproductive outcomes. - **Combined oral contraceptive pills/COCs (4)** are the first-line pharmacological treatment for menstrual irregularity and hyperandrogenism in PCOS when fertility is not desired. They regulate cycles, suppress ovarian androgen production, and reduce hirsutism and acne. - **Anti-androgens (2)** such as spironolactone are used in first-line management of moderate-to-severe hirsutism and acne in PCOS, typically in combination with COCs. They block androgen receptors or inhibit androgen synthesis, providing additional benefit for hyperandrogenic symptoms like the increased facial hair in this patient. *1,2,3* - **Laparoscopic ovarian drilling (1)** is a second-line surgical treatment reserved for anovulatory infertility in PCOS patients who fail to respond to ovulation induction with clomiphene citrate. It is NOT a first-line treatment for menstrual irregularity and hirsutism. - While lifestyle modifications (3) and anti-androgens (2) are appropriate first-line components, the inclusion of ovarian drilling makes this combination incorrect as a first-line approach. *1,2,4* - **Laparoscopic ovarian drilling (1)** is an invasive procedure indicated only as second-line therapy for specific cases of anovulatory infertility, not for initial management of irregular cycles and hirsutism. - Although anti-androgens (2) and COCs (4) are appropriate first-line pharmacological treatments, the inclusion of ovarian drilling excludes this from being a correct first-line treatment combination. *1,3,4* - This combination includes two appropriate first-line treatments: **lifestyle modifications (3)** and **combined oral contraceptive pills (4)**. - However, **laparoscopic ovarian drilling (1)** is a second-line or third-line surgical intervention for very specific indications (anovulatory infertility resistant to medical management), making this combination incorrect as a first-line approach for this clinical presentation.
Question 4: All of the following are tests done for Turner mosaic screening except?
- A. Karyotype
- B. FISH
- C. Serum FSH (Correct Answer)
- D. Buccal smear
Explanation: ***Serum FSH*** - **Serum Follicle-Stimulating Hormone (FSH)** levels are used to assess ovarian function and can be elevated in conditions like Turner syndrome due to **gonadal dysgenesis**, but it is a **functional test**, not a screening tool for mosaicism. - While elevated FSH is a clinical feature of Turner syndrome, it does not directly screen for the chromosomal mosaicism itself. *Karyotype* - **Karyotyping** is the **gold standard** for diagnosing Turner syndrome and its mosaics by visualizing the entire set of chromosomes [1]. - It can identify various forms of mosaicism involving the X chromosome, where some cells have 45,XO and others have 46,XX or other variations [1]. *FISH* - **Fluorescence in situ hybridization (FISH)** is a molecular cytogenetic technique used to detect specific chromosomal abnormalities, including those associated with Turner mosaicism. - It uses DNA probes that bind to specific regions of the X chromosome, allowing for the rapid detection of **aneuploidy** or deletions that might indicate mosaicism [2]. *Buccal smear* - A **buccal smear**, historically used for **Barr body** analysis, can provide an initial screening for X chromosome abnormalities. - The presence of Barr bodies (inactive X chromosomes) can help differentiate between 45,XO (no Barr body) and mosaic variants like 45,XO/46,XX (variable number of Barr bodies). **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 54-55. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Genetic Disorders, pp. 186-187.
Question 5: A 30-year-old housewife reports with 6 months amenorrhea. Her serum LH and FSH are high with low estradiol levels. What is the most likely cause of amenorrhea in this context?
- A. Premature menopause (Correct Answer)
- B. Polycystic ovarian disease
- C. Exercise induced
- D. Pituitary tumour
Explanation: ***Premature menopause*** - **High LH and FSH** with **low estradiol** levels indicate primary ovarian failure, where the ovaries are no longer responding to pituitary stimulation. - In a 30-year-old woman, this ovarian failure presenting as 6 months of amenorrhea is consistent with **premature menopause** (also known as premature ovarian insufficiency). *Polycystic ovarian disease* - Characterized by **high LH:FSH ratio** (typically LH higher than FSH) and **high estrogen** due to peripheral conversion of androgens, which is contrary to the low estradiol observed here. - Presents with features like **hirsutism**, acne, and menstrual irregularities, but typically not with primary ovarian failure. *Exercise induced* - **Exercise-induced amenorrhea** (hypothalamic amenorrhea) is characterized by **low or normal LH and FSH** and **low estradiol**, reflecting inadequate GnRH pulsatility from the hypothalamus, not primary ovarian failure. - This condition is a form of **secondary amenorrhea** due to a disruption in the hypothalamic-pituitary-ovarian axis, often seen in athletes or people with low body fat. *Pituitary tumour* - A **pituitary tumor** can cause amenorrhea by various mechanisms, such as secreting prolactin (prolactinoma) which **inhibits GnRH**, leading to **low LH, FSH, and estradiol**. - Alternatively, a large non-functional tumor might cause hypopituitarism, also resulting in **low gonadotropins and estradiol**, which contradicts the high LH and FSH seen in this patient.
Question 6: All of the following are true about hot flushes EXCEPT:
- A. Possible role of serotonin is implicated
- B. Can start several years before menopause
- C. Can persist for several years after menopause
- D. Can affect the entire body, not just specific regions (Correct Answer)
Explanation: ***Can affect the entire body, not just specific regions*** - While hot flashes are experienced as a **systemic sensation of heat**, they are predominantly characterized by intense warmth in the **upper body**, head, and neck, along with sweating, flushing, and palpitations. - The sensation of warmth is usually perceived to emanate from the chest or neck, spreading upwards, rather than encompassing the entire body uniformly. *Possible role of serotonin is implicated* - The **pathophysiology of hot flashes** is complex and involves neurotransmitter systems, with **serotonin** (5-HT) pathways in the brain playing a significant role in thermoregulation. - Drugs that modulate serotonin, such as **selective serotonin reuptake inhibitors (SSRIs)**, have been shown to reduce the frequency and severity of hot flashes. *Can start several years before menopause* - **Vasomotor symptoms**, including hot flashes, often begin during the **perimenopause**, which is the transitional period leading up to menopause. - This phase typically starts several years before the final menstrual period, when **hormonal fluctuations**, particularly in estrogen levels, become more pronounced. *Can persist for several years after menopause* - For many women, hot flashes can continue for an extended period into the **postmenopausal years**. - Studies indicate that the duration of hot flashes can vary widely, with some women experiencing them for **more than 10 years** after their final menstrual period.
Question 7: A 46-year-old woman presents for her annual examination. Her main complaint is frequent sweating episodes with a sensation of intense heat starting at her upper chest and spreading up to her head. These have been intermittent for the past 6 to 9 months but are gradually worsening. She has three to four flushing/sweating episodes during the day and two to three at night. She occasionally feels her heart race for about a second, but when she checks her pulse it is normal. She reports feeling more tired and has difficulty with sleep due to sweating. She denies major life stressors. She also denies weight loss, weight gain, or change in bowel habit. Her last menstrual cycle was 3 months ago. Physical examination is normal. Which treatment is most appropriate in alleviating this woman's symptoms?
- A. Estrogen plus progesterone (Correct Answer)
- B. Citalopram
- C. Estrogen
- D. Levothyroxine
Explanation: ***Estrogen plus progesterone*** - This patient's symptoms (hot flashes, night sweats, fatigue, sleep disturbance, irregular menses) are highly suggestive of **perimenopause/menopause**. **Hormone replacement therapy (HRT)** with estrogen and progesterone is the most effective treatment for managing severe menopausal symptoms. - Adding **progesterone** is crucial for women with an intact uterus to prevent **endometrial hyperplasia** and **endometrial cancer** caused by unopposed estrogen therapy. *Citalopram* - **Selective serotonin reuptake inhibitors (SSRIs)** like citalopram can reduce the frequency and severity of hot flashes, but they are generally reserved for women who cannot take or prefer not to take HRT due to contraindications or concerns. - SSRIs are less effective than HRT for severe vasomotor symptoms and do not address other menopausal symptoms like vaginal dryness or bone loss. *Estrogen* - While estrogen is the primary hormone for alleviating menopausal symptoms, administering **unopposed estrogen** to a woman with an intact uterus significantly increases the risk of **endometrial hyperplasia** and **endometrial carcinoma**. - Progesterone is necessary to counteract the proliferative effects of estrogen on the endometrium, preventing these risks. *Levothyroxine* - **Levothyroxine** is used to treat **hypothyroidism**, a condition that can cause fatigue, weight changes, and menstrual irregularities. - However, the patient's primary symptoms of prominent hot flashes and night sweats are not characteristic of hypothyroidism, and her physical examination is normal, making this diagnosis less likely.
Question 8: Which of the following is NOT effective in controlling the hot flushes of menopause in a woman?
- A. Raloxifene (Correct Answer)
- B. Isoflavones
- C. Hormone replacement therapy
- D. Tibolone
Explanation: ***Raloxifene*** - **Raloxifene** is a selective estrogen receptor modulator (SERM) that acts as an estrogen agonist in bone tissue, helping to prevent osteoporosis, but it is an estrogen antagonist in other tissues and can actually worsen or induce **hot flushes**. - Its primary indications are for the prevention and treatment of **osteoporosis** in postmenopausal women, and for the reduction of risk of invasive breast cancer in high-risk women. *Isoflavones* - **Isoflavones** (e.g., from soy) are phytoestrogens that can have weak estrogenic effects, and some women find them helpful in reducing the frequency and severity of **hot flushes**, though efficacy varies. - They bind to estrogen receptors, potentially mitigating the sudden drops in estrogen that lead to **vasomotor symptoms**. *Hormone replacement therapy* - **Hormone replacement therapy (HRT)**, which involves estrogen with or without progestin, is the most effective treatment for **menopausal hot flushes**. - By replacing declining estrogen levels, HRT directly addresses the underlying cause of **vasomotor instability**. *Tibolone* - **Tibolone** is a synthetic steroid that has estrogenic, progestogenic, and androgenic properties, and it is effective in relieving **menopausal hot flushes**. - It specifically targets estrogen receptors in the hypothalamus, which helps to stabilize **thermoregulatory control** and reduce hot flushes.
Question 9: For a menopausal patient having hot flashes, which of the following can be given as treatment?
- A. Progesterone
- B. 17β-estradiol (Correct Answer)
- C. Danazol
- D. Gonadotropin
Explanation: ***17β-estradiol*** - **Estrogen therapy** is the **gold standard** and **most effective treatment** for menopausal vasomotor symptoms including hot flashes - **17β-estradiol** directly replaces the declining ovarian estrogen levels that cause hot flashes - Recommended by all major guidelines (NAMS, ACOG, IMS) as **first-line therapy** for moderate to severe vasomotor symptoms - Available in various formulations: oral, transdermal patches, gels, and sprays - In women with an intact uterus, progestogen must be added to prevent endometrial hyperplasia *Progesterone* - **Progestogens** (synthetic progesterone) are primarily used to **protect the endometrium** when estrogen is prescribed to women with an intact uterus - Can provide **mild relief** of hot flashes in some women, but are **significantly less effective** than estrogen therapy - May be considered as **monotherapy** only when estrogen is contraindicated (e.g., breast cancer, thromboembolic disease) - **Not first-line treatment** for vasomotor symptoms *Danazol* - An **attenuated androgen** with anti-estrogenic and androgenic properties - Used primarily for **endometriosis** and **fibrocystic breast disease** - Would **worsen menopausal symptoms** including hot flashes due to its anti-estrogenic effects - Contraindicated in menopause management *Gonadotropin* - **FSH and LH** levels are already **markedly elevated** in menopause due to lack of negative feedback from ovarian hormones - Used in **fertility treatment**, not menopausal symptom management - Exogenous gonadotropin administration is **inappropriate and ineffective** for hot flashes
Question 10: In menopause, which of the following is seen:
- A. High FSH (Correct Answer)
- B. High progesterone
- C. High estrogen
- D. Low FSH
Explanation: ***High FSH*** - In **menopause**, the ovaries lose their ability to produce **estrogen** and **progesterone**, leading to a decline in their levels. - This decline in ovarian hormones removes the **negative feedback** on the **hypothalamus** and **anterior pituitary**, causing a compensatory increase in **gonadotropin-releasing hormone (GnRH)**, **follicle-stimulating hormone (FSH)**, and **luteinizing hormone (LH)**. *High progesterone* - **Progesterone** levels are typically **low** in menopause because the ovaries are no longer ovulating or producing the corpus luteum, which is the primary source of progesterone. - While progesterone is important in the normal menstrual cycle, its production ceases after the final menstrual period. *High estrogen* - **Estrogen** levels are generally **low** in menopause due to the cessation of ovarian follicular activity. - The decline in estrogen is responsible for many menopausal symptoms, such as hot flashes and vaginal dryness. *Low FSH* - **Low FSH** is typically seen in conditions where there is sufficient **estrogen** and **progesterone** exerting negative feedback on the pituitary, or in primary pituitary/hypothalamic dysfunction. - In menopause, the **lack of ovarian hormones** specifically causes FSH (and LH) levels to be significantly elevated.
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free